CNBX Pharmaceuticals Inc. (CNBX) Change in Accured Expenses (2011 - 2026)

CNBX Pharmaceuticals (CNBX) has 16 years of Change in Accured Expenses data on file, last reported at -$67096.0 in Q2 2026.

• Quarterly Change in Accured Expenses fell 536.34% year-over-year to -$67096.0 in Q2 2026, while the trailing twelve-month figure through May 2026 was $78246.0 (up 2879.61% YoY) and the FY2025 annual result came in at $101217.0, up 132.61% from the prior year.
• Change in Accured Expenses eased to -$67096.0 in Q2 2026, from $45456.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $304689.0 in Q2 2023 to a low of -$67096.0 in Q2 2026.
• A 5-year average of $49549.2 and a median of $28446.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2022 — Change in Accured Expenses jumped 41304.52% — and 2026, when it slumped 536.34%.
• Tracing CNBX's Change in Accured Expenses over 5 years: stood at $135784.0 in 2022, then plunged by 103.34% to -$4533.0 in 2023, then sank by 73.11% to -$7847.0 in 2024, then surged by 356.76% to $20148.0 in 2025, then tumbled by 433.02% to -$67096.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$67096.0 (Q2 2026), $45456.0 (Q1 2026), and $20148.0 (Q4 2025), per Business Quant data.